Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Payables (2021 - 2025)

ARS Pharmaceuticals' Payables history spans 5 years, with the latest figure at $37.9 million for Q4 2025.

  • For Q4 2025, Payables rose 284.48% year-over-year to $37.9 million; the TTM value through Dec 2025 reached $37.9 million, up 284.48%, while the annual FY2025 figure was $37.9 million, 284.48% up from the prior year.
  • Payables for Q4 2025 was $37.9 million at ARS Pharmaceuticals, up from $8.4 million in the prior quarter.
  • Across five years, Payables topped out at $37.9 million in Q4 2025 and bottomed at $126000.0 in Q3 2022.
  • The 5-year median for Payables is $4.4 million (2021), against an average of $7.7 million.
  • The largest annual shift saw Payables plummeted 92.67% in 2022 before it skyrocketed 358.22% in 2024.
  • A 5-year view of Payables shows it stood at $5.6 million in 2021, then plummeted by 97.73% to $126000.0 in 2022, then skyrocketed by 1609.52% to $2.2 million in 2023, then surged by 358.22% to $9.9 million in 2024, then surged by 284.48% to $37.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Payables are $37.9 million (Q4 2025), $8.4 million (Q3 2025), and $9.9 million (Q4 2024).